Strive for cancer towards the "era of slow disease management" nuclear medical technology new breakthrough "Prague therapy" shiny worldwide

On July 8th, the "Prague Treatment" version 1.0 research results created by Professor Zhang Liyuan, a Nuclear Industry General Hospital (Suzhou University Affiliated Hospital). Frontiers in Immunology (https://doi.org/10.3389/fimmu.2022.952066). It is worth mentioning that the research results of the Prague treatment 1.0 plan published this time lasted only 17 days. At the same time, a successful case of Prague's treatment of refractory gastric cancer three months ago, a group contributed to the magazine three months ago (https://doi.org/10.3389/fimmu.2022.926740).

Two days before and after the two consecutive days, it has been to be important academic magazines in the field of immunology, reflecting the recognition of international colleagues in Prague. For the new technologies of late refractory tumors, "Prague Treatment" has been widely used in clinical clinical clinical clinical in China before the award of this award. The team is trying to pull the "dysfunction" into the "camp".

"Prague Treatment" surrendered "refractory gastric cancer"

The cases published this time vividly demonstrated the effective control of Prague therapy for tumor disease.

In March 2020, Mr. Jin was diagnosed with gastric adenocarcinoma. Although it was treated with radical surgery and timely auxiliary chemotherapy treatment, unfortunately, the tumor metastasis soon. After that, Mr. Jin experienced targeted treatment and chemotherapy, but the condition was still difficult to control. At this time, Mr. Jin suffered fatigue, dissection, anemia, oral ulcer and hypoproteinemia caused by traditional anti -tumor treatment. Mr. Jin's body was getting worse, and his physical and mental fatigue almost lost his confidence to continue anti -cancer.

Mr. Jin finally hoped that he hoped to join Prague in November 2020 to treat the 1.0 plan. After only 3 months, the tumor disappeared and disappeared. The clinical evaluation of its efficacy was completely alleviated (CR). During the treatment period, Mr. Jin did not have severe toxic and sideline. His long -lost smile came back. The fighting spirit of anti -cancer was back. Although Mr. Jin reviewed in February 2022 and found a new metastatic lesion, at this time Prague treatment had been iterated to the 3.0 era. After six weeks of Prague 3.0 treatment, the tumor was found to be "traces" after testing, and clinical evaluation reached CR again. At present, Mr. Jin has returned to the state of "no tumor" and working and living normally.

"Prague Treatment" -The patients with PD-1/PD-L1 inhibitors "re-ignition hope"

The PD-1/PD-L1 inhibitor enters the era of tumor treatment into the era of immunotherapy, but it is still not ideal for the effectiveness and relief period of PD-1/PD-L1 inhibitors alone. For patients with PD-1/PD-L1 inhibitors failed, Prague treatment may still re-ignite the hope of patients!

In March 2017, Ms. Shen was diagnosed with advanced lung cancer and lost the opportunity to surgery. On the road of anti-cancer for more than three years, she moved to many well-known domestic hospitals in China, and received chemotherapy, radiotherapy, anti-vascular generating therapy, driving genetic targeted therapy, T drugs (PD-L1 inhibitors) and K drugs (PD (PD (PD (PD (PD -1 inhibitors) and other comprehensive treatment, but still cannot control the progress of tumor.

The mountains and rivers are doubtful, and there is another village of Liu Dark.

In September 2020, Ms. Shen entered the Prague treatment 1.0 plan. After three months of treatment, Ms. Shen reached a fully clinical relief (CR) and maintained to this day.

"Different from the traditional treatment of" killing the enemy for one thousand self -harming 800 ", Prague treatment can 'four or two pounds', and the quality of life at the same time is also improved. I hope more patients with late tumors like me can benefit from this technology. , So that long -term survival. "In July of this year, Ms. Shen took the initiative to be the" image ambassador "of" Prague treatment "during the review.

"Past and present life" of "Prague Treatment"

The "previous life" treated by Prague stems from radiologists' exploration of "radiation far -distance effects". The radioactive long partial effect refers to the phenomenon of degeneration of tumor lesions in the non -irradiation area outside of the irradiated area. As early as 1953, there were reports of radiation far -range effects, but the incidence of radiation long -distance effects has been extremely low, which is the so -called encounter.

In 2006, Professor Zhang Liyuan's team learned that when he studied a literature, he learned that Listelobug, who accepted the radiation, could be used as a vaccination mouse to prevent the re -infection of Listera. Inspired by this literature, the research team boldly speculate that the radiation far -part effect may be a appearance of "tumor vaccine effect" to produce "tumor vaccine effects". Since then Clinical trials of Prague treatment 1.0 plan.

Prague therapy is a combination of PD-1/PD-L1 inhibitor, radiotherapy and (and) granulocyte-macrophage stimulus factor (GM-CSF). Due to the three element PD-1 in the treatment plan /PD-L1 Inhibitor, Radiotherapy and GM-CSF's first letter combination is "Prag". At the same time, "Prague" is of great significance in the field of radiation therapy, which is named "Prague therapy". As the clinical trials of the Prague treatment series of the treatment series were successfully carried out, many refractory tumors were overcome one by one. The mid -term research results of the clinical trials of Prague's 1.0 plan were released in 2020 at the annual meeting of the American Clinical Oncology Society (ASCO 2020), which made a loud voice of ASCO China. The ASCO Annual Conference is the world's largest, most academic level, and the most authoritative clinical oncology conference. Many important studies have found and clinical trial results will be published at the ASCO Annual Conference. In order to further improve the efficacy of Prague treatment, the team upgraded Prague treatment to the 2.0 era by cleverly added Bitukin-2. In 2021, China's original targeted chemotherapy (antibody coupletic drug ADC)-Vidici-Mipido is listed. Prague research team combined with HER-2 positive patients. , Pushed Prague to the 3.0 era, and continuously defeated a variety of tumors such as refractory pancreatic cancer and refractory cricket adenocarcinoma.

Innovation, the diligent Prague team is starting to study the Prague 2.0X treatment for the refractory bone metastasis and Prague 4.0P treatment against peritoneal metastasis.

"Prague Treatment" in the new era of "different diseases"

In 2019, Professor Zhang Liyuan was elected as the deputy chairman of the Tumor and Radiotherapy Commission of the Traditional Chinese and Western Medicine Society in Jiangsu Province, and often collided with Chinese and Western medicine.

Prague treatment is a kind of pan -tumor treatment, and it is repeatedly tried in the treatment of various tumors. Zhang Liyuan believes that radiotherapy as a drug can stimulate the "vitality" of PD-1/PD-L1 inhibitors. The "igniter" of radiotherapy stimulates the trend of "star fire", which is precisely the vivid practice of raw radiological therapy and successfully integrated into the theory of "different diseases" theory of traditional Chinese medicine.

The concept of "different diseases" can be traced back to the "Yellow Emperor's Internal Classic", and "Golden Slimorizer" has practiced the spirit of "different diseases" in dialectical theory. "The same scripture is the same side, and the same disease is also the same." TCM treatment is not mainly based on the similarities and differences in the disease, but the similarities and differences in evidence. The same certificate can be used by the same method, and different certificates must be used. "

Tumor is "disease", immune escape is "prove".

Zhang Liyuan explained that with the development of precision radiotherapy technology, "large -segmentation" radiotherapy can be implemented. No matter what kind of tumor can be exposed after being "strike", antigen exposure, and the exposed antigen can become a "tumor vaccine" This is the theoretical basis that Prague treatment can "differentiated diseases". Do not care about what kind of tumors, as long as various immunomotive agents are applied, any tumor may be controlled by Prague treatment. "Prague treatment is to help the body to establish effective immune control of tumors, and then fundamentally obtain the advantages of prevention and treatment of tumors, which also practiced the concept of traditional Chinese medicine cure."

"Tumor Vaccine" rooted "innovation highland"

"Prague Treatment" began in 2019. As soon as he came out, he stunned the oncology world.

At that time, the mid -term research results of Prague treatment were verbally reported by the academic conference of radiological tumor therapy for radiological tumor therapy for the Chinese Medical Association. Since then, they will go abroad and have become the Annual Conference of the United States Clinical Oncology Society (ASCO), European radiation therapy and and in Europe. The "ESTRO) Meeting of the Academy of Science and the United States Radi Oncology Society (Astro) has won the championship three times in the national tumor academic competition. Since 2020, the Hebiko Foundation (CSCO) has listed it as "black technology" for tumor diagnosis and treatment for two consecutive years.

From inspiration to innovation of ideas, to scientific verification, Prague treatment benefits the fertile soil that nourishes its growth. Nuclear Industry General Hospital not only fully supports the clinical innovation of nuclear medical technology applications, but also formed a lot of experts composed of experts in the fields of oncology, imaging diagnosis, nutrition, psychology, immunology, pharmacy, statistics, computer science and other fields. Disciplinary team. With the strong support of the Suzhou Municipal Government, the team established a key laboratory of tumor radiological immunotherapy in Suzhou. From the perspective of Zhang Liyuan, it is precisely because of soil cultivation and mechanism that the "tumor vaccine" can be quickly available, and safe applications are continuously iterated.

It is understood that in order to support the development of "Prague therapy" technology, China Nuclear Group established a China Nuclear Nuclear Medical Tumor Prague Treatment Research Center in the Nuclear General Industry General Hospital, and rated the "Prague treatment" technology as the "13th Five -Year Plan" scientific and technological innovation of China Nuclear Group. The results are included in the "Fourteenth Five -Year Plan" science and technology development plan of Baoyuan.

In recent years, under the leadership of Professor Zhang Liyuan, Prague Treatment has toured more than 200 games in more than 20 provinces and cities across the country, and taught the experience of Prague treatment to the industry.Patients benefited as soon as possible.At present, many well -known hospitals such as Peking University Third Hospital, Xiangya Hospital of Central South University, Cancer Hospital of Fudan University, Shandong Cancer Hospital, Chongqing Cancer Hospital, and Jiangsu Traditional Chinese Medicine Hospital have successively conducted Prague treatment.Practice has proven that the condition of many patients with late -stage refractory tumors was effectively controlled by Prague, and the toxic and side effects were mild, creating a "Prague Miracle" in the industry.Zhang Liyuan said, "We are trying to turn cancer into a chronic disease and then gradually overcome it. As a tumor doctor, Prague treatment is only a milestone on our innovation road, and the pace of exploration will never stop."

- END -